Coronavirus (COVID-19) Collection
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies
As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations.2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation
On December 31, 2019, aggregate cases of an apparently new respiratory syndrome were reported in the city of Wuhan, China by Chinese national health authorities to the World Health Organization (WHO) (Huang et al., 2020; Organization WH, 2020a). As of 13h February 2020, there have been 45 171 cases reported to the World Health Organization with 1104 deaths (Organization WH, 2020a). Outside China there have been 441 confirmed cases reported from 24 countries (Organization WH, 2020a; Organization WH, 2020b).
